Probiotics use to treat irritable bowel syndrome
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Irritable bowel syndrome (IBS) is a common chronic gastrointestinal (GI) tract disorder with significant disability and a considerable financial burden to health service due to the consumption of resources including investigations, physician time, and cost of treatment. Despite availability of multiple treatment options, there is still poor functional recovery. AREAS COVERED: Probiotics has been investigated as a promising treatment for IBS, and have demonstrated beneficial effects in some patients. There are many clinical trials investigating the therapeutic benefits of probiotics in IBS but most of them are heterogenic in terms of dose or species used and clinical endpoints. However, recent major meta-analyses revealed benefits of probiotics in patients with IBS. Inhibition of binding of pathogenic bacteria to intestinal epithelial cells, enhancing barrier function of intestinal epithelial, acidification of the colon, suppression of the growth of pathogens, modulation of immunity, inhibition of visceral hypersensitivity, alteration in mucosal response to stress, and improvement of bowel dysmotility are among mechanisms that probiotics may act. Most commonly used probiotics come from the genera Bifidobacterium and Lactobacillus but other species are in trial. EXPERT OPINION: Although further studies are still needed, current evidences are almost enough to convince experts that probiotics are efficient in the treatment of IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448 · cited 1×
“infantis 35624 alleviated symptoms in IBS [51,52].”
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review
Moayyedi, P., Ford, A. C., Talley, N. J., Cremonini, F., Foxx-Orenstein, A. E., Brandt, L. J., & Quigley, E. M. M. (2010) · Gut · doi:10.1136/gut.2008.167270 · Cited by 728 · cited 2×
“Few recent systematic reviews and meta-analyses concluded that probiotics appear to be effective in patients with IBS [6,13,23,25,29,32-37].”
BackgroundNiedzielin, K., Kordecki, H., & Birkenfeld, B. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200110000-00004 · Cited by 506
Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact
Hungin, A. P. S., Chang, L., Locke, G. R., Dennis, E. H., & Barghout, V. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02463.x · Cited by 494 · cited 3×
“According to Rome III, there are several types of IBS including constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed IBS (sometimes diarrhea, sometimes constipation) (IBS-M).”
BackgroundKim, H. J., Camilleri, M., Mckinzie, S., Lempke, M. B., Burton, D. D., Thomforde, G. M., & Zinsmeister, A. R. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01543.x · Cited by 468 · cited 7×
“The prevalence of each subtype varies in studies; reports claim IBS-D [7] or IBS-M [8] to be the most common, but some reports are in favor of equal prevalence [9].”
BackgroundInfluentialKim, H. J., Vazquez Roque, M. I., Camilleri, M., Stephens, D., Burton, D. D., Baxter, K., Thomforde, G., & Zinsmeister, A. R. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00695.x · Cited by 400 · cited 1×
“VSL#3 appears promising in the relief of abdominal bloating in patients with IBS-D [43] as it reduces flatulence scores and retards colonic transit without altering bowel function in patients with IBS [44].”
BackgroundKAJANDER, K., MYLLYLUOMA, E., RAJILIĆ‐STOJANOVIĆ, M., KYRÖNPALO, S., RASMUSSEN, M., JÄRVENPÄÄ, S., ZOETENDAL, E. G., DE VOS, W. M., VAPAATALO, H., & KORPELA, R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03542.x · Cited by 367
The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review
Brenner, D. M., Moeller, M. J., Chey, W. D., & Schoenfeld, P. S. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.25 · Cited by 362 · cited 1×
“Few recent systematic reviews and meta-analyses concluded that probiotics appear to be effective in patients with IBS [6,13,23,25,29,32-37].”
BackgroundKAJANDER, K., HATAKKA, K., POUSSA, T., FÄRKKILÄ, M., & KORPELA, R. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02579.x · Cited by 361
Meta-analysis of probiotics for the treatment of irritable bowel syndrome
McFarland, L. V., & Dublin, S. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2650 · Cited by 341
AGRAWAL, A., HOUGHTON, L. A., MORRIS, J., REILLY, B., GUYONNET, D., GOUPIL FEUILLERAT, N., SCHLUMBERGER, A., JAKOB, S., & WHORWELL, P. J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03853.x · Cited by 334 · cited 1×
“As seen in Table 1, other mixtures of probiotics are also useful for the treatment of IBS symptoms [57-65].”
BackgroundA systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome
Hoveyda, N., Heneghan, C., Mahtani, K. R., Perera, R., Roberts, N., & Glasziou, P. (2009) · BMC Gastroenterology · doi:10.1186/1471-230x-9-15 · Cited by 297
Guandalini, S., Magazzù, G., Chiaro, A., La Balestra, V., Di Nardo, G., Gopalan, S., Sibal, A., Romano, C., Canani, R. B., Lionetti, P., et al. (2010) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3181ca4d95 · Cited by 273
GAWROŃSKA, A., DZIECHCIARZ, P., HORVATH, A., & SZAJEWSKA, H. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03175.x · Cited by 251 · cited 1×
“Also Lactobacillus GG did not show significant effect in the treatment of abdominal pain in children with IBS but helped relieve symptoms such as abdominal distention [47-49].”
BackgroundSen, S., Mullan, M. M., Parker, T. J., Woolner, J. T., Tarry, S. A., & Hunter, J. O. (2002) · Digestive Diseases and Sciences · doi:10.1023/a:1020597001460 · Cited by 245 · cited 1×
“For example, LP299V seems to have a beneficial effect in patients with IBS and reduces pain or flatulence [38,39] but in other studies this probiotic did not appear to have positive effect on colonic fermentation, GI symptoms, rectal sensitivity, or improvement of symptoms [40,41] but L.”
BackgroundA Randomized Controlled Trial of Lactobacillus GG in Children With Functional Abdominal Pain
Francavilla, R., Miniello, V., Magistà, A. M., De Canio, A., Bucci, N., Gagliardi, F., Lionetti, E., Castellaneta, S., Polimeno, L., Peccarisi, L., et al. (2010) · Pediatrics · doi:10.1542/peds.2010-0467 · Cited by 242
NIV, E., NAFTALI, T., HALLAK, R., & VAISMAN, N. (2005) · Clinical Nutrition · doi:10.1016/j.clnu.2005.06.001 · Cited by 191
Review article: probiotics and prebiotics in irritable bowel syndrome
SPILLER, R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03750.x · Cited by 190
Ringel-Kulka, T., Palsson, O. S., Maier, D., Carroll, I., Galanko, J. A., Leyer, G., & Ringel, Y. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31820ca4d6 · Cited by 174
SIMRÉN, M., ÖHMAN, L., OLSSON, J., SVENSSON, U., OHLSON, K., POSSERUD, I., & STRID, H. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04183.x · Cited by 169
Sinn, D. H., Song, J. H., Kim, H. J., Lee, J. H., Son, H. J., Chang, D. K., Kim, Y.-H., Kim, J. J., Rhee, J. C., & Rhee, P.-L. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0196-4 · Cited by 163
WILLIAMS, E. A., STIMPSON, J., WANG, D., PLUMMER, S., GARAIOVA, I., BARKER, M. E., & CORFE, B. M. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03848.x · Cited by 156 · cited 1×
“As seen in Table 1, other mixtures of probiotics are also useful for the treatment of IBS symptoms [57-65].”
BackgroundEfficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials
Nikfar, S., Rahimi, R., Rahimi, F., Derakhshani, S., & Abdollahi, M. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-008-9335-z · Cited by 155
Self-citationDrouault-Holowacz, S., Bieuvelet, S., Burckel, A., Cazaubiel, M., Dray, X., & Marteau, P. (2008) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2007.06.001 · Cited by 151
Choi, C. H., Jo, S. Y., Park, H. J., Chang, S. K., Byeon, J.-S., & Myung, S.-J. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318204593e · Cited by 144 · cited 1×
“boulardii improved IBS-QOL better than placebo but was not superior for individual symptoms in patients with IBS-D or mixed-type IBS [54].”
BackgroundTSUCHIYA, J., BARRETO, R., OKURA, R., KAWAKITA, S., FESCE, E., & MAROTTA, F. (2004) · Chinese Journal of Digestive Diseases · doi:10.1111/j.1443-9573.2004.00176.x · Cited by 108
Enck, P., Zimmermann, K., Menke, G., & Klosterhalfen, S. (2009) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027702 · Cited by 100
Pharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome
Chey, W. D., Maneerattaporn, M., & Saad, R. (2011) · Gut and Liver · doi:10.5009/gnl.2011.5.3.253 · Cited by 89 · cited 2×
“The presence of IBS is recognized by clinical criteria, which include the presence of episodic abdominal pain or discomfort in association with altered bowel habits without weight loss or anemia, bloating and flatulence in the absence of identifiable biochemical or structural abnormalities [1-3].”
BackgroundEffect of probiotics on symptoms in Korean adults with irritable bowel syndrome
Hong, K. S., Kang, H. W., Im, J. P., Ji, G. E., Kim, S. G., Jung, H. C., Song, I. S., & Kim, J. S. (2009) · Gut and Liver · doi:10.5009/gnl.2009.3.2.101 · Cited by 75
Andriulli, A., Neri, M., Loguercio, C., Terreni, N., Merla, A., Cardarella, M. P., Federico, A., Chilovi, F., Milandri, G. L., De Bona, M., et al. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31817fadd6 · Cited by 75
Dai, C., Guandalini, S., Zhao, D.-H., & Jiang, M. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1126-5 · Cited by 60
The Rationale and Clinical Effectiveness of Probiotics in Irritable Bowel Syndrome
Ringel, Y., & Ringel-Kulka, T. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31822d32d3 · Cited by 44
Cited by
The impact of diet and lifestyle on gut microbiota and human health
Conlon, M., & Bird, A. (2014) · Nutrients · doi:10.3390/nu7010017 · Cited by 1,567
A systematic review of the safety of probiotics
Didari, T., Solki, S., Mozaffari, S., Nikfar, S., & Abdollahi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.872627 · Cited by 367
Self-citationMcFarland, L. V. (2013) · World Journal of Meta-Analysis · doi:10.13105/wjma.v1.i3.102 · Cited by 33
Metadata
- Authors
- Hosseini, A., Nikfar, S., & Abdollahi, M.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2012-08-16
- Volume
- 12
- Issue
- 10
- Pages
- 1323-1334
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2136761187
- Cited by
- 35
- References
- 32
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.